Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non‐small‐cell lung cancer: Systematic review and meta analysis

BACKGROUND: The correlation between epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) and EGFR sensitive mutation subtypes in advanced or metastatic non‐small cell lung cancer (NSCLC) remains uncertain. We performed this meta‐analysis to determine different clinical outcomes be...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yinghui, Ren, Zuen, Wang, Jinghui, Zhang, Shucai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930959/
https://www.ncbi.nlm.nih.gov/pubmed/27385982
http://dx.doi.org/10.1111/1759-7714.12343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930959/
https://www.ncbi.nlm.nih.gov/pubmed/27385982
http://dx.doi.org/10.1111/1759-7714.12343

Ejemplares similares